🇺🇸 FDA
Pipeline program

Deramiocel (CAP-1002)

CAP-1002-DMD-04

Phase 3 mab active

Quick answer

Deramiocel (CAP-1002) for Muscular Dystrophies is a Phase 3 program (mab) at CAPRICOR THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
CAPRICOR THERAPEUTICS, INC.
Indication
Muscular Dystrophies
Phase
Phase 3
Modality
mab
Status
active

Clinical trials